These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24052461)

  • 1. Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?
    Izzedine H; Soria JC; Escudier B
    J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 6. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
    Tesařová P; Tesař V
    Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
    Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria and hypertension with tyrosine kinase inhibitors.
    Kandula P; Agarwal R
    Kidney Int; 2011 Dec; 80(12):1271-7. PubMed ID: 21900879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor.
    Ferrara N
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):789-91. PubMed ID: 19164810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
    Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.